Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

134.93 -0.26 (-0.19%)
Streaming Delayed Price Updated: 12:03 PM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
52 53 Next >
News headline image
2 gene-editing stocks reshaping hereditary disease treatments
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal 
Via MarketBeat
News headline image
Why Is Neurology Focused Cingulate Stock Trading Higher Today? ↗
On Tuesday, Cingulate Inc (NASDAQ: CING) received FDA guidance f 
Via Benzinga
News headline image
Why Is Cytokinetics (CYTK) Stock Up 70% Today? ↗
With Cytokinetics hitting a homerun with its heart failure drug, CYTK stock skyrocketed in part due to takeover interest. 
Via InvestorPlace
News headline image
Bristol Myers Squibb Takes On Novartis, Eli Lilly With RayzeBio $4B Deal In Radiopharmaceuticals ↗
Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire RayzeBio Inc (NASDAQ: RYZB) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of < 
Via Benzinga
News headline image
These 3 Big Pharma Stocks Are Making Big Plays With AI ↗
Opportunity is in the air with AI, and these pharma giants are seizing the moment. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
(NVS) - Analyzing Novartis's Short Interest ↗
 
Via Benzinga
News headline image
(NVS) - Analyzing Novartis's Short Interest ↗
 
Via Benzinga
News headline image
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug ↗
The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy... 
Via Benzinga
News headline image
Fusion's Pharma's Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% Upside ↗
RBC Capital Markets initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), saying the radiopharmaceutical industry is a burgeoning area in therapeutics following the green light for Novartis... 
Via Benzinga
News headline image
Lantheus Downgraded Due To Reliance On PNT2002; Analyst Cites Comparable Profile To Novartis' Drug ↗
Monday, Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Phase 3 SPLASH trial of 177Lu-PNT2002 in metastatic c 
Via Benzinga
News headline image
Are November’s 3 Biggest Stock Losers Worth Snapping Up Now? ↗
The market was like an iceberg with only a few winners showing but that means there are a lot of the biggest stock losers worth getting now. 
Via InvestorPlace
News headline image
FDA Approves Merck's Drug Belzutifan For Type Of Advanced Kidney Cancer In Pretreated Cancer Patients ↗
The FDA approved Merck & Co Inc's (NYSE: MRK) Welireg (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for adult patients with advanced renal cell carcinoma (RCC) following a... 
Via Benzinga
News headline image
Novartis' Newly FDA-Approved Rare Blood Disorder Drug Aces Phase 3 Study In Ultra Rare Kidney Failure Disease ↗
Novartis AG (NYSE: NVS) announced  
Via Benzinga
News headline image
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks ↗
Regulators are already on the case, and their findings will have financial impacts. 
Via The Motley Fool
News headline image
A Comprehensive Study Exploring Breast Cancer Treatment Market : Key Players Gilead Sciences, Astellas, Celgene
Get an extensive Breast Cancer Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry. 
Via SBWire
News headline image
Zoetis Stock A Good Companion For Your Portfolio? Shares Rising ↗
Reflecting strong fundamentals, Zoetis stock boasts a best-possible A SMR Rating (sales+profit margins+return on equity) on an A-to-E scale. 
Via Investor's Business Daily
News headline image
Novartis' Rare Blood Disorder Therapy Scores FDA Approval ↗
The FDA approved Novartis AG's (NYSE 
Via Benzinga
News headline image
Allergy Treatment Market Know Faster Growing Segments Now: Akorn, Pfizer, Novartis, Mylan N.V ↗
Global Allergy Treatment Market Breakdown by Application (Hospitals, Specialty Clinics, Homecare, Others) by Type (Eye Allergy, Food Allergy, Skin Allergy, Asthma, Rhinitis, Others) by Treatment... 
Via SBWire
News headline image
Anti-Inflammatory Drugs Market Boosting the Growth Worldwide 2030
Get Anti-inflammatory Drugs Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis. 
Via SBWire
News headline image
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies ↗
Tuesday, the FDA said it received reports of patients developing T-cell malig 
Via Benzinga
News headline image
3 Healthcare Stocks to Pick Up Before the Year-End Rally ↗
Explore the potential of healthcare stocks as the U.S. charges ahead with $4.3 trillion in healthcare spending 
Via InvestorPlace
News headline image
Novartis Outlines Pure-Play Strategy Progress After Generics Business Spin-Off ↗
Novartis AG (NYSE: NVS) has outlined the progress made in delivering its pure-play strategy, focused on four core therapeutic areas (Cardiovascular-Renal-Metabolic, Immunology, Neuroscience, Oncology),... 
Via Benzinga
Gene Therapy Market Research: Exploring Market Size, Business Growth, Career Prospects, Industry Trends, and Projections for 2028 ↗
Northbrook, IL 60062 -- (SBWIRE) -- 11/27/2023 -- In May 2022, Novartis AG (Switzerland) received US FDA approval for KYMRIAH (Tisagenlecleucel) for a third indication, including relapsed or refractory... 
Via SBWire
News headline image
Olema Stock Has Soared 551% This Year. Its CEO Thinks It's Still Undervalued. ↗
The company is working on treatments for breast cancer in a market worth $15 billion, according to the CEO. 
Via Investor's Business Daily
News headline image
2 overlooked stocks that crushed earnings but traded lower
As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results 
Via MarketBeat
News headline image
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal ↗
Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and... 
Via Talk Markets
News headline image
Diversifying Your Portfolio With Plant-Based Options ↗
Investors see profit potential in the plant-based market due to rising consumer demand, ESG focus, and the growth of vegan products in various industries, including pharmaceuticals. However, market... 
Via Talk Markets
News headline image
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On ↗
Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector. 
Via The Motley Fool
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Verve Loses A Third Of Its Value As Safety Concerns Plague Its Gene-Editing Drug ↗
Patients had big decreases in LDL cholesterol. But there were some side effects. 
Via Investor's Business Daily
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.